{"filings":[{"id":90663,"accession_number":"0001493152-26-015365","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics terminates CFO Alexander Arrow, effective April 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Alexander Arrow notified on March 31, 2026 that employment will be terminated.","Termination effective April 30, 2026; no successor or interim CFO announced.","Company common stock (PTIX) and warrants (PTIXW) trade on OTC Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100376,"accession_number":"0001493152-26-008605","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics appoints William Nichols as President; base salary $350k, 40% bonus target, 1% option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William (Bill) Nichols, Jr., age 51, appointed President effective Feb 3, 2026.","Prior senior commercial leadership roles at bluebird bio, Dova Pharmaceuticals, and Bristol-Myers Squibb.","Annual base salary $350,000; eligible for annual target bonus of 40% of base salary.","Employment agreement includes option grant equal to ~1.0% of fully diluted share count.","No family relationships or transactions requiring Item 404(a) disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100375,"accession_number":"0001493152-26-007800","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","1.02","2.01","3.02","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.","PTIX returns 100% of Phytanix Bio shares; receives back all PTIX common and preferred stock issued as consideration.","PTIX pays Phytanix Bio $300,000 at closing and $10,000 upon receipt of specified financial information.","Litigation styled Protagenic v. Alterola Biotech et al. dismissed with prejudice.","Mutual releases and indemnification provisions between parties; former Phytanix stockholders resign from PTIX positions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100374,"accession_number":"0001493152-26-000263","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).","Trading on Nasdaq will cease at close of Jan 2, 2026; OTC trading expected to start Jan 5, 2026.","Company has withdrawn its hearing request, making delisting final.","Company intends to evaluate steps to regain compliance and seek relisting on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116703,"accession_number":"0001493152-25-025159","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.","Company also cited for delayed Form 10-Q for quarter ended September 30, 2025 (Rule 5250(c)(1)).","Will request hearing before Nasdaq Hearings Panel; automatic 15-day stay of suspension granted.","Common stock and warrants will continue trading on Nasdaq during automatic stay and any extended stay.","Company expects to file the overdue 10-Q imminently but no assurance Panel will grant relief."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116702,"accession_number":"0001493152-25-020881","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jennifer Chao resigns from Protagenic Therapeutics Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Chao resigned from the Board of Directors on November 3, 2025, effective immediately.","No disagreements were reported between Ms. Chao and the Company.","Her departure reduces the board size; no replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116701,"accession_number":"0001493152-25-020444","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics files suit to rescind Phytanix Bio acquisition or seek damages","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed Verified Complaint in Delaware Chancery Court on October 28, 2025.","Seeks rescission of May 15, 2025 Share Exchange Agreement acquiring Phytanix Bio.","Alternatively seeks damages and an order compelling delivery of audited financials.","Lawsuit challenges the entire transaction; no settlement or resolution disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133146,"accession_number":"0001493152-25-013851","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K/A","filed_at":"2025-09-17T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Protagenic Therapeutics updates auditor consent for Phytanix acquisition; no material news","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company files Exhibit 23.1 with consent of GreenGrowth CPAs Inc.","Financial statements and pro forma data from prior filing remain unchanged.","Acquisition of Phytanix Bio was previously reported on May 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133145,"accession_number":"0001641172-25-025737","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K/A","filed_at":"2025-08-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).","On Aug 8, Board approved restructuring: suspended preclinical programs, terminated CEO Barrett Evans and COO Colin Stott.","Restructuring expected to cut annual operating expenses by ~$8M; focus on Phase 2 trial of PT00114.","Changed auditor from MaloneBailey to GreenGrowth CPAs; fiscal year changed from Dec 31 to March 31, effective Aug 7, 2025.","Historical Phytanix loss from ops $2.6M for year ended Mar 31, 2025; cash used in ops $1.8M; ~$1M ATM capacity remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133150,"accession_number":"0001641172-25-025274","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01","4.01","7.01","9.01"],"status":"ready","headline":"Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.","Received Nasdaq deficiency notice on Aug 20, 2025 due to late filing of Q2 2025 Form 10-Q; trading continues under PTIX.","Expects to file overdue 10-Q soon; will submit compliance plan within 60 days if needed.","Completed first dose injection for all subjects in multiple-dose portion of Phase I trial of PT00114; topline safety data expected by end of September."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133149,"accession_number":"0001641172-25-023588","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.05","5.02","5.03","8.01"],"status":"ready","headline":"Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.","Annual operating expenses to be reduced by ~$8 million when fully implemented; one-time charges not yet estimable.","CEO Barrett Evans and COO Colin Stott terminated effective immediately; both remain on the Board.","All preclinical programs (PHYX-001 through PHYX-005) paused; company pursuing partnerships or out-licensing.","Fiscal year-end changed from Dec 31 to Mar 31; transition report on Form 10-QT for Apr 1–Jun 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133148,"accession_number":"0001641172-25-021552","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics granted Japan patent for modified stilbenoid epilepsy drug candidates","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japanese Patent Office granted Patent JP 7714571B on July 18, 2025, covering modified stilbenoid compounds.","Patent runs until March 31, 2041, providing exclusivity for treating epilepsy and seizures.","Builds on previously granted UK patent GB2609814 for same program.","Japanese pharma market worth >$85B; global epilepsy drug market expected to reach $18.7B by 2034.","Company expects to expand patent protection to other territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133147,"accession_number":"0001641172-25-020802","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics appoints Timothy R. Wright as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy R. Wright appointed to board effective July 18, 2025 as Class II director, term expires at 2026 annual meeting.","Board determined Wright is independent under Nasdaq rules; board now has three independent directors.","Wright is Executive Chairman of Isosceles (since 2019) and President/CEO of BIORG, INC. (since 2023).","He also serves on the board of Agenus Inc. (since 2006) and previously held executive roles at Covidien/Medtronic and Teva.","Wright will receive standard non-employee director compensation as described in the January 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149754,"accession_number":"0001641172-25-016979","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Protagenic Therapeutics declares rights offering at $0.01 per share to preserve ownership after Phytanix acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized distribution of one Right per common share held as of July 7, 2025 record date.","Each Right entitles holder to purchase 4.57 common shares at $0.01 per share, subject to stockholder approval.","Rights become exercisable only after stockholder meeting approves Phytanix acquisition and share issuance; exercisable for up to 6 months.","Rights initially trade with Common Stock, become separable after approval; Rights Agreement with Equiniti Trust Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149753,"accession_number":"0001641172-25-011878","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.","Proceeds will fund working capital and advance peptide-based drug candidates for CNS disorders.","Company previously announced business combination with Phytanix Bio Inc. on May 19, 2025.","Combined entity has six drug programs spanning stress, epilepsy, obesity, and other indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149752,"accession_number":"0001641172-25-011633","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Protagenic Therapeutics exchanges 459,420 warrants for 367,544 shares at 0.8 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant Exchange Agreement with unaffiliated holder to cancel 459,420 warrants for 367,544 common shares.","Exchange relies on Section 3(a)(9) exemption; shares issued without restrictive legends.","Transaction to be completed within six months of May 20, 2025.","Net reduction of 91,876 potential shares outstanding compared to exercise of warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149751,"accession_number":"0001641172-25-011387","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025","Issued 117,690 common shares, 5,705 Series C Preferred, 950,000 Series C-1 Preferred, and 20,000 Series D Preferred to Phytanix stockholders","Appointed Barrett Evans as President and CEO, Colin Stott as COO and director, and Jennifer Chao as director; Andrew Slee promoted to Chief Development Officer","Resignations of directors Khalil Barrage, Tim Wright, and Robert Stein effective immediately before closing","Filed certificates of designation for Series C and C-1 Non-Voting Convertible Preferred Stock on May 15, 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149750,"accession_number":"0001641172-25-008455","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Protagenic Therapeutics effects 1-for-14 reverse stock split to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-14 ratio effective 12:01 a.m. ET on May 5, 2025.","Approved by stockholders at April 18, 2025 special meeting; board set ratio to comply with Nasdaq Rule 5550(a)(2).","Common stock trades on Nasdaq under symbol PTIX with new CUSIP 74365N301; warrants continue under PTIXW.","Fractional shares rounded up; proportionate adjustments to outstanding options, warrants, and RSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149749,"accession_number":"0001641172-25-006649","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.","Intended to bring PTIX into compliance with Nasdaq minimum bid price rule 5550(a)(2).","Share count to drop from ~8.24M to ~588,750; fractional shares rounded up.","Stockholders approved split on April 18, 2025 with ratio range 1:10 to 1:20; board set at 1:14.","Symbol PTIX unchanged; new CUSIP 74365N301; no change in authorized shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149748,"accession_number":"0001641172-25-005368","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protagenic shareholders approve reverse stock split at ratio 1:10 to 1:20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting held April 18, 2025; 4,049,963 shares present out of 7,241,443 entitled.","Reverse split proposal passed: 3,560,865 for, 333,824 against, 155,274 abstain.","Board authorized to choose exact ratio between 1:10 and 1:20 and timing before Jan 31, 2026.","Adjournment proposal also approved: 3,552,086 for, 336,677 against, 161,200 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168780,"accession_number":"0001493152-25-008040","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protagenic Therapeutics reprices outstanding stock options to $0.2655 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved repricing of options under 2006 and 2016 Equity Incentive Plans.","Original exercise prices ranged from $1.74 to $19.92; repriced to $0.2655 per share.","New exercise price equals closing common stock price on February 21, 2025.","Action intended to retain and incentivize option holders, including officers and employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168779,"accession_number":"0001493152-25-007942","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protagenic Therapeutics shareholders approve all five proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Garo H. Armen and Brian J. Corvese as Class III directors with ~1.87M and ~1.85M for votes.","Approved repricing of outstanding stock options: 1,803,833 for, 184,143 against, 70,373 abstain.","Ratified MaloneBailey LLP as auditor for FY2024: 3,492,771 for, 81,987 against, 72,564 abstain.","Approved issuance of common stock warrant shares from Oct 2024 agreements: 1,928,277 for, 58,942 against.","Approved amendment to 2016 Equity Plan allowing option repricing without shareholder approval: 1,803,817 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168778,"accession_number":"0001493152-25-004143","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic receives Nasdaq delisting notice for failing to regain $1 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified on Jan 22, 2025 that company failed to regain compliance with minimum bid price Rule 5550(a)(2).","Company not eligible for second 180-day compliance period due to not meeting initial listing requirements.","Company will present to Nasdaq Hearings Panel on Jan 30, 2025; no immediate delisting effect.","Deficiency originally reported on July 24, 2024; stock closed below $1 for 30 consecutive business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168777,"accession_number":"0001493152-25-002448","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics gets Nasdaq notice for missing annual meeting; sets Feb 21, 2025 meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 15, 2025 for failing to hold annual meeting within 12 months of FY 2023 end (Listing Rule 5620(a)).","Company has scheduled annual meeting to occur no later than February 21, 2025 to regain compliance.","No immediate effect on listing of PTIX or PTIXW on Nasdaq Capital Market.","Will submit matter to Nasdaq Hearings Panel as part of ongoing listing discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168776,"accession_number":"0001493152-25-001516","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics enters ATM sales agreement for up to $1.2M with B. Riley Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to At Market Issuance Sales Agreement with B. Riley Securities, dated Jan 9, 2025.","Company may sell up to $1.2 million of common stock from time to time in at-the-market offerings.","Agent commission is 3.0% of gross sales price; Company can terminate agreement on notice.","Sales will be made under effective shelf registration statement (333-280244), declared effective Jan 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185908,"accession_number":"0001493152-24-048431","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protagenic Therapeutics appeals Nasdaq delisting; hearing set for Jan 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1)).","Company failed to regain compliance by Nov 18, 2024 extension deadline; delisting determination issued Nov 19.","Appeal filed Nov 27; hearing stayed pending Panel decision; hearing scheduled Jan 30, 2025.","Materials due Jan 10, 2025; no assurance Panel will grant more time to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185907,"accession_number":"0001493152-24-047376","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq delisting notice; stock suspension set for Nov 29","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement by Nov 18, 2024, after extension.","Nasdaq delist determination letter received Nov 19; trading of PTIX stock to suspend on Nov 29 unless appeal.","Company may request Nasdaq hearing to stay delisting, but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185906,"accession_number":"0001493152-24-043615","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics closes $1.275M private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement on Nov 4, 2024; sold 1,948,295 shares of common stock.","Issued series A warrants (18-month term) and series B warrants (5-year term), each exercisable at $0.64 per share.","Gross proceeds of $1.275M; net proceeds to be used for working capital.","Brookline Capital Markets acted as sole placement agent for the offering.","Warrants exercisable only after stockholder approval date; no proceeds from warrants included in gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185905,"accession_number":"0001493152-24-042964","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics raises $1.275M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,948,295 shares (or pre-funded warrants) at $0.64 per share ($0.89 for insiders).","Also issued Series A warrants (18-month term) and Series B warrants (5-year term), both exercisable at $0.64.","Gross proceeds ~$1.275 million; net proceeds for working capital.","Closing expected on or before November 4, 2024; Brookline Capital Markets acted as placement agent.","Directors and officers subject to 90-day lock-up from closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202477,"accession_number":"0001493152-24-036925","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.","Results from multiple dose portion of Phase I study for PT00114 expected Q2 2025.","Initiation of Phase IIa study for PT00114 expected Q3 2025.","Company will provide further updates to clinical development schedule as it becomes clearer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202476,"accession_number":"0001493152-24-029295","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified PTIX on July 24, 2024 of non-compliance with minimum $1.00 bid price for 30 consecutive business days.","Company has until January 20, 2025 to regain compliance; requires closing bid of $1.00 for at least 10 consecutive days.","If not compliant by Jan 20, 2025, PTIX may qualify for an additional 180-day cure period if it meets other listing standards.","Failure to cure could lead to delisting; the company may appeal any delisting determination to a Nasdaq hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218606,"accession_number":"0001493152-24-021383","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq deficiency notice for failing minimum equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company's stockholders' equity fell below Nasdaq's $2.5M minimum as of March 31, 2024.","Must submit a compliance plan by July 8, 2024; Nasdaq may grant up to 180-day extension.","If plan rejected, common stock (PTIX) faces potential delisting; no immediate effect.","Company exploring collaborations and capital raising to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218605,"accession_number":"0001493152-24-020973","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics reports zero clinically-relevant adverse events in Phase 1 single dose portion for PT00114","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.","Multiple ascending dose portion of the trial is planned to commence later this year.","PT00114 targets stress reduction as root cause for PTSD, depression, anxiety, addiction, and potentially obesity.","Investor call scheduled for May 22 at 10:00 am ET to discuss safety data and implications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238497,"accession_number":"0001493152-24-010741","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics resolves Nasdaq delisting notice, regains compliance with bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq Listing Rule 5550(a)(2) on March 19, 2024.","Closing bid price stayed above $1.00 for ten consecutive trading days (Mar 5-18, 2024).","Previously faced potential delisting by May 19, 2024; notice now closed.","Original deficiency notice received Nov 21, 2023 for bid price below $1.00 for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256010,"accession_number":"0001493152-23-045033","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protagenic Therapeutics reports 2023 annual meeting voting results; two Class II directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert B. Stein, MD, PhD elected with 974,293 votes for, 56,765 withheld; Jennifer Buell, PhD elected with 963,089 for, 67,969 withheld.","Ratification of MaloneBailey LLP as auditor passed with 2,324,009 for, 9,482 against, 2,451 abstain.","Directors Stein and Buell will serve Class II terms until 2026 annual meeting; board composition updated.","Total shares present at meeting: 2,336,032 out of 4,330,959 entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256009,"accession_number":"0001493152-23-043098","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified PTIX on Nov 21, 2023 that common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.","Company has 180 calendar days, until May 19, 2024, to regain compliance with bid price requirement.","To regain compliance, closing bid price must be at least $1.00 for ten consecutive business days.","If not cured by May 19, 2024, PTIX may be eligible for an additional 180-day period if it meets other listing standards.","Stock continues trading on Nasdaq Capital Market under symbol PTIX; no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311259,"accession_number":"0001493152-23-008494","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics announces 1-for-4 reverse stock split to comply with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5:01 p.m. ET March 22, 2023; split-adjusted trading Nasdaq opens March 23, 2023.","Goal: meet Nasdaq Rule 5550(a)(2) $1.00 minimum closing price for continued listing.","Outstanding shares reduced from ~17,285,261 to ~4,321,315; no fractional shares—rounded up to next whole.","Proportionate adjustments to exercise prices and shares underlying outstanding options, warrants, and equity awards.","Authorized shares and par value unchanged; new CUSIP 74365N202; ticker remains PTIX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329866,"accession_number":"0001493152-22-033864","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Shareholders approve reverse split; company updates PT00114 trial timeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved a reverse stock split of 1:2 to 1:4, with board discretion on exact ratio.","Elected Khalil Barrage and Timothy R. Wright as Class I directors until 2025.","PT00114: U.S. IND submission expected by end of 2022; German ethics committee approved, awaiting BfArM.","Company anticipates Phase I start in Q1 2023 and first human safety readouts within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347445,"accession_number":"0001493152-22-024982","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protagenic receives CMC questions from European regulator; expects Q4 2022 trial start","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received CMC (Chemistry, Manufacturing and Controls) questions from a European regulatory authority on August 30, 2022.","Company is addressing the questions and currently expects to commence clinical trials in Q4 2022.","Protagenic is also finalizing its US submission for the same trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363898,"accession_number":"0001493152-22-018038","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Protagenic Therapeutics updates clinical milestones; plans US re-submission and Phase I/IIa trial in Germany by Q3 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company completing requirements to answer regulatory questions and begin US re-submission process.","Submitting filing in Europe to commence Phase I/IIa trial at a major CRO site in Germany anticipated to start Q3 2022.","Further updates to clinical development schedule to be provided as it becomes clearer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401464,"accession_number":"0001493152-21-024665","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2021-10-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Protagenic Therapeutics resolves Nasdaq audit committee compliance issue, appoints Joshua Silverman","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified the Company of audit committee composition non-compliance from April 27 to September 30, 2021.","Dr. Jennifer Buell resigned from the Audit Committee; Joshua Silverman appointed effective October 1, 2021.","With Silverman's appointment, the Company is now in compliance with Nasdaq Listing Rule 5605(c)(2)(A).","It was later determined that Dr. Buell met independence requirements; she remains an independent board member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401463,"accession_number":"0001493152-21-024376","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Protagenic Therapeutics stockholders approve classified board structure; directors re-elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["At Sep 29 annual meeting, all six director nominees elected with votes ranging from 8.37M to 8.88M for each.","Stockholders approved classified board amendment (8.82M for, 150.9K against); filed with Delaware on Oct 1, 2021.","Board classified into three classes: Class I (Buell, Stein) term expiring 2022, Class II (Barrage, Silverman) 2023, Class III (Armen, Corvese) 2024.","MaloneBailey LLP ratified as independent auditor for FY2021 (10.60M for, 2.8K against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420419,"accession_number":"0001493152-21-020615","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2021-08-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.","Q2 2021 net loss $2.6M (vs $0.6M in Q2 2020); G&A expense rose to $2.2M.","Closed $13.2M public offering of 3.18M units at $4.15/unit; cash $11.9M as of June 30, 2021.","Initial Phase I/IIa data readout expected 1H 2022, final readout Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420418,"accession_number":"0001493152-21-017696","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2021-07-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics delays PT00114 clinical trial start to Q4 2021 after FDA request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested ready-to-inject clinical vials instead of local formulation; company refiling IND.","Patient enrollment now expected to begin in Q4 2021 (previously earlier timeline).","Company states implementing FDA guidance adds benefit of controlling final drug product formulation.","Press release dated July 23, 2021; IND filed June 29, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420417,"accession_number":"0001493152-21-016077","cik":1022899,"company_name":"Protagenic Therapeutics, Inc.new","ticker":"PTIX","form_type":"8-K","filed_at":"2021-07-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Protagenic Therapeutics enters ATM equity offering agreement for up to $10M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into ATM Sales Agreement with B. Riley Securities and EF Hutton to sell up to $10M of common stock.","Commission of 3.0% of gross sales price; agents use commercially reasonable efforts to sell shares.","Offering made under S-3 shelf registration (No. 333-256790) effective June 23, 2021.","Company not obligated to sell shares; agreement can be terminated by either party upon notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":942812.854934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}